JP Morgan analyst Eric Joseph downgrades Lyell Immunopharma (NASDAQ:LYEL) from Overweight to Neutral and lowers the price target from $15 to $5.
JP Morgan Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.